Addendum

Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95

Status
Status: Commission completed
Project no.
A21-147
Last updated

Report documents

  1. Addendum

    Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95

    published on
    Document type
    PDF document, 533 kB, EN, not accessible

Dossier assessment

Indication:

Refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite appropriate restoration of volume and use of catecholamines or other available vasoconstrictive therapies

Result of dossier assessment:

Unchanged after addendum:
Added benefit not proven.

Additional information

Federal Joint Committee (G-BA)

2022-01-06 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A21-147
Commission
Commission awarded on 23.11.2021 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Heart and circulation
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-95
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form